Featuring an interview with Dr Laura Huppert, including the following topics:

• General overview of antibody-drug conjugate (ADC) structure and function; mechanisms of resistance to ADCs (0:00)
• Preventing and managing toxicities associated with trastuzumab deruxtecan (5:44)
• Selecting between sacituzumab govitecan and datopotamab deruxtecan for patients with metastatic breast cancer; common toxicities associated with these 2 agents (9:30)
• Potential use of ADCs in the first line for metastatic triple-negative breast cancer (mTNBC) (16:13)
• Case: A woman in her mid 40s with mTNBC receives sacituzumab govitecan and pembrolizumab in the first-line setting (18:25)
• CNS penetration and activity of ADCs in the treatment of breast cancer (22:27)
• Use of trastuzumab deruxtecan for HER2-ultralow mTNBC; promising trials of ADCs and other therapies for mTNBC (24:24)
• Treatment options in the second line and beyond for patients with HR-positive mBC that is HER2-negative, HER2 low or HER2 ultralow (27:05)
• Case: A woman in her late 50s with HR-positive, HER2-low mBC experiences disease progression on multiple lines of therapy (30:51)
• Ongoing evaluation of ADCs in the localized disease setting (35:42)
• Novel therapeutic approaches for leptomeningeal disease in patients with breast cancer (38:38)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics:

• Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00)
• Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18)
• Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10)

CME information and select publications

Featuring perspectives from Dr Jeremy S Abramson, Dr Jennifer Crombie and Dr Laurie H Sehn, moderated by Dr Abramson, including the following topics: 

• Introduction (0:00)
• Integrating Bispecific Antibodies into the Management of Follicular Lymphoma (FL) — Dr Crombie (2:08)
• ICurrent Role of CD19-Directed Chimeric Antigen Receptor T-Cell Therapy for FL — Dr Abramson (21:01)
• Other Recently Approved and Emerging Novel Therapies for Relapsed/Refractory FL — Dr Sehn (40:52)

CE information and select publications

Featuring an interview with Dr Ghayas Issa, including the following topics:

• Mechanism of action and efficacy of menin inhibitors (0:00)
• Presentation and management of differentiation syndrome (13:31)
• Role of menin inhibitors in other cancers (18:19)
• Case: A woman in her mid 40s with KMT2A-rearranged acute myeloid leukemia (AML) after treatment for breast cancer (20:51)
• Mechanisms of resistance to menin inhibition in AML (26:53)
• Case: A woman in her early 70s with monocytic AML and multiple mutations including NPM1 experienced complete response with ziftomenib (32:31)
• Mechanism of action of menin inhibitors as differentiation agents (38:05)
• Similarities and differences between approved and investigational menin inhibitors under clinical development for the treatment of AML (45:55)
• Dual targeted therapy and other novel treatment approaches under clinical evaluation with menin inhibitors (51:25)
• Other investigational therapeutic strategies in AML (54:39)

CME information and select publications

Featuring a slide presentation and related discussion from Dr Ghayas Issa, including the following topics:

• Evolution of menin inhibitors for acute myeloid leukemia (AML) (0:00)
• Side effects of menin inhibition (10:54)
• Mechanisms of resistance to menin inhibition in AML (15:08)

CME information and select publications

Featuring perspectives from Dr Sara A Hurvitz and Dr Sara M Tolaney, including the following topics:

• Introduction: View from Outer Space (0:00)
• Hormone Receptor-Positive Breast Cancer (6:23)
• HER2-Positive Breast Cancer (40:54)
• Triple-Negative Breast Cancer (52:48)

CME information and select publications

Featuring case presentations and related discussion from Dr Sara A Hurvitz and Dr Sara M Tolaney, including the following topics:

• Case: A woman in her mid 50s with localized HR-negative, HER2-positive breast cancer — Dr Tolaney (0:00)
• Case: A woman in her mid 40s with localized HR-positive breast cancer with a germline BRCA2 mutation — Dr Tolaney (7:08)
• Case: A woman in her early 30s with HR-negative, HER2-positive metastatic breast cancer with one isolated liver metastasis — Dr Tolaney (11:30)
• Case: A woman in her early 50s with metastatic triple-negative breast cancer — Dr Tolaney (17:52)
• Case: A woman in her early 30s with localized HR-positive, HER2-negative breast cancer — Dr Hurvitz (31:49)
• Case: A woman in her early 60s with HR-positive, HER2-negative metastatic breast cancer with concurrent PIK3CA and ESR1 mutations — Dr Hurvitz (40:39)
• Case: A woman in her early 40s with recurrent HR-positive advanced breast cancer with a PIK3CA mutation — Dr Hurvitz (51:28)
• Case: A woman in her early 50s with HR-positive, HER2-negative breast cancer eligible for the SERENA-6 switching strategy — Angela DeMichele, MD, MSCE (58:41)

CME information and select publications

Featuring perspectives from Prof Meletios-Athanasios (Thanos) C Dimopoulos, Dr Hans Lee, and Dr Noopur Raje, moderated by Dr Joseph Mikhael, including the following topics: 

• Introduction (0:00)
• Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory (R/R) Multiple Myeloma (MM) — Dr Raje (3:17)
• Integrating Bispecific Antibodies into the Management of R/R MM — Dr Lee (20:38)
• Potential Role of Antibody-Drug Conjugates and Cereblon E3 Ligase Modulators in Therapy for MM — Prof Dimopoulos (40:37)

CE information and select publications

Featuring an interview with Dr Kevin Kalinsky, including the following topics:

• Patient-Reported Outcomes from the TROPION-Breast01 Study (0:00)
  • Pernas S et al. Datopotamab deruxtecan (Dato-DXd) vs chemotherapy (CT) in previously treated inoperable or metastatic hormone receptor-positive, HER2-negative (HR+/HER2-) breast cancer (BC): Patient-reported outcomes from the TROPION-Breast01 study. ASCO 2024;Abstract 1006.
• Indirect Comparison of Sacituzumab Govitecan and Datopotamab Deruxtecan for Advanced Breast Cancer (5:04)
  • Pathak N et al. Indirect comparison of sacituzumab govitecan (SG) and datopotamab deruxtecan (Dato-DXd) in advanced breast cancer (aBC): Safety and efficacy analysis. San Antonio Breast Cancer Symposium 2024;Abstract P1-02-02.
• BEGONIA: A Phase Ib/II Study of Datopotamab Deruxtecan with Durvalumab as First-Line Treatment for Unresectable Advanced Triple-Negative Breast Cancer (9:53)
  • Schmid P et al. Datopotamab deruxtecan (Dato-DXd) + durvalumab (D) as first-line (1L) treatment for unresectable locally advanced/metastatic triple-negative breast cancer (a/mTNBC): Updated results from BEGONIA, a phase Ib/II study. ESMO 2023;Abstract 379MO.
• Advances in the Use of TROP2-Targeted Antibody-Drug Conjugates for Breast Cancer: Mechanisms, Clinical Applications and Future Directions (15:35)
  • Tong Y et al. Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions. Front Immunol 2024;15:1495675. Abstract

CME information and select publications

Featuring an interview with Prof Peter Schmid, including the following topics:

• Response to immunotherapy in breast cancer subtypes (0:00)
• Tolerability of TROP2 antibody-drug conjugates (ADCs) for metastatic breast cancer (mBC) (3:51)
• Approaches to therapy for patients with HR-negative HER2-low and HER2-ultralow mBC (13:03)
• ADC structure and treatment-related adverse events (19:02)
• Available data from the Phase III ASCENT-04 trial evaluating sacituzumab govitecan with pembrolizumab as first-line therapy for patients with PD-L1-positive advanced triple-negative breast cancer (23:06)
• Novel ADCs and bispecific antibodies under investigation for mBC (28:30)
• Comparing datopotamab deruxtecan and sacituzumab govitecan for HR-positive disease (33:01)
• Clinical investigator perspectives on the Phase III DESTINY-Breast09 trial evaluating first-line trastuzumab deruxtecan with or without pertuzumab versus THP (docetaxel/rastuzumab/pertuzumab) for HER2-positive mBC (35:06)

CME information and select publications